-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $410

Benzinga·07/14/2026 13:42:56
Listen to the news
B of A Securities analyst Tazeen Ahmad maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $460 to $410.